Human IL-4 Protein, premium grade
分子別名(Synonym)
IL4,BCGF1,BSF1
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-4, premium grade (IL4-H4218) is expressed from human 293 cells (HEK293). It contains AA His 25 - Ser 153 (Accession # P05112-1).
Predicted N-terminus: His 25
Human IL-4, premium grade (IL4-H4218), designed for preclinical stage, has the same activity and performance with GMP Human IL-4 (GMP-L04H26), which enables a seamless transition from preclinical development to clinical phases. Premium Grade product offer a cost efficient alternative of GMP Grade products for the early development phase when safety of raw materials is not top priority. By using Premium Grade products in early development phase, you can transition easily into clinical and commercial phase without need to revalidate the raw materials and modify manufacturing process.
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 15.0 kDa. The protein migrates as 19 kDa±3 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
宿主蛋白殘留(Host Cell Protein)
<0.5 ng/μg of protein tested by ELISA.
宿主核酸殘留(Host Cell DNA)
<0.02 ng/μg of protein tested by qPCR.
無菌(Sterility)
Negative
支原體(Mycoplasma)
Negative.
純度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-HPLC.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白細(xì)胞介素-4是一種誘導(dǎo)幼稚輔助性T細(xì)胞(Th0細(xì)胞向Th2細(xì)胞)分化的細(xì)胞因子。在存在IL-4和IL-13(Th-2型反應(yīng)中產(chǎn)生的細(xì)胞因子,特別是在過敏和寄生蟲感染期間)的情況下,巨噬細(xì)胞被差異激活,并且該細(xì)胞因子是白細(xì)胞介素4受體的配體。白細(xì)胞介素4受體也與IL13結(jié)合,這可能有助于該細(xì)胞因子和IL13的許多重疊功能。STAT6是一種信號轉(zhuǎn)導(dǎo)和轉(zhuǎn)錄激活因子,已被證明在介導(dǎo)這種細(xì)胞因子的免疫調(diào)節(jié)信號中起著核心作用。最近,研究人員發(fā)現(xiàn),細(xì)胞因子IL-4在幾種基因缺陷小鼠品系(包括Itk,KLF2,CBP和Id3)的胸腺中先天CD8+T細(xì)胞的發(fā)育中起關(guān)鍵作用,而之前沒有暴露于抗原。
關(guān)鍵字: IL-4;IL-4蛋白;IL-4重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。